Loading
Orelabrutinib is InnoCare's BTK-blocking pill for chronic lymphocytic leukaemia and mantle cell lymphoma, approved in China in 2020.
Approved by the NMPA in December 2020 for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma and for relapsed or refractory mantle cell lymphoma, with relapsed or refractory marginal zone lymphoma added in 2023, the first approval for any BTK inhibitor in that disease. It competes with zanubrutinib and ibrutinib in China's NRDL and is being tested in primary central nervous system lymphoma and, outside oncology, in multiple sclerosis.
Irreversible, highly selective covalent inhibitor of BTK with minimal off-target kinase activity, designed for once-daily dosing and central nervous system penetration. Connects to BTK (Bruton tyrosine kinase).
1.Orelabrutinib slips into a pocket on BTK (Bruton tyrosine kinase).
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2020 | Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma |
| China | 2023 | Relapsed or refractory marginal zone lymphoma |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Orelabrutinib" OR ABSTRACT:"Orelabrutinib" OR TITLE:"Yinuokai" OR ABSTRACT:"Yinuokai" OR TITLE:"ICP-022" OR ABSTRACT:"ICP-022") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Orelabrutinib, not a curated reading list.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors and the tag china.